Alpine Immune Sciences, Inc. (ALPN): Price and Financial Metrics

Alpine Immune Sciences, Inc. (ALPN)

Today's Latest Price: $8.62 USD

0.14 (1.65%)

Updated Sep 29 4:00pm

Add ALPN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 376 in Biotech

See all "A" rated Strong Buy stocks

ALPN Stock Summary

  • With a price/sales ratio of 68.33, Alpine Immune Sciences Inc has a higher such ratio than 96.56% of stocks in our set.
  • Revenue growth over the past 12 months for Alpine Immune Sciences Inc comes in at 420.63%, a number that bests 98.44% of the US stocks we're tracking.
  • In terms of volatility of its share price, ALPN is more volatile than 94.09% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Alpine Immune Sciences Inc are SRRK, RCUS, FULC, GLYC, and TBIO.
  • Visit ALPN's SEC page to see the company's official filings. To visit the company's web site, go to
ALPN Daily Price Range
ALPN 52-Week Price Range

ALPN Stock Price Chart Technical Analysis Charts

ALPN Price/Volume Stats

Current price $8.62 52-week high $15.00
Prev. close $8.48 52-week low $2.05
Day low $8.30 Volume 26,213
Day high $8.64 Avg. volume 301,889
50-day MA $9.00 Dividend yield N/A
200-day MA $5.43 Market Cap 205.03M

Alpine Immune Sciences, Inc. (ALPN) Company Bio

Alpine Immune Sciences, Inc. is focused on developing novel protein‐based immunotherapies using its proprietary Variant Ig Domain vIgD platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine’s vIgDs are developed using a process known as directed evolution, which can potentially produce proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to both oncology and inflammatory diseases. The company formed following a July, 2017 merger with Nivalis Therapeutics.

ALPN Latest News Stream

Event/Time News Detail
Loading, please wait...

ALPN Latest Social Stream

Loading social stream, please wait...

View Full ALPN Social Stream

Latest ALPN News From Around the Web

Below are the latest news stories about Alpine Immune Sciences Inc that investors may wish to consider to help them evaluate ALPN as an investment opportunity.

Alpine Immune Sciences secures equity capital of $60M

Alpine Immune Sciences ([[ALPN]] +1.6%) inks an agreement for the direct sale of 5.1M  units, each consisting of one common share and 0.3 of a 3.5 year warrant to purchase one common share at $12.74, at price of $10.1175 per unit. The transaction also includes 0.8M prefunded warrant units at the...

Seeking Alpha | July 24, 2020

Alpine Immune Sciences Announces $60 Million Private Placement

Alpine Immune Sciences Announces $60 Million Private Placement

Yahoo | July 24, 2020

Did Business Growth Power Alpine Immune Sciences' (NASDAQ:ALPN) Share Price Gain of 126%?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) shareholders have seen the share price descend 13% over the month. But that...

Yahoo | July 22, 2020

The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio

The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio

Yahoo | July 8, 2020

Alpine Immune Sciences, Inc. (ALPN) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Alpine Immune Sciences, Inc. (ALPN).

Yahoo | July 8, 2020

Read More 'ALPN' Stories Here

ALPN Price Returns

1-mo 5.64%
3-mo -15.32%
6-mo 199.31%
1-year 133.60%
3-year -25.69%
5-year -81.69%
YTD 124.48%
2019 4.35%
2018 -67.14%
2017 25.00%
2016 -71.06%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7191 seconds.